<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:39:42Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/11135" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/11135</identifier><datestamp>2026-10-18T20:39:02Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Synthesis of newly designed hydrazones, in vitro and in silico studies, and structure-activity relationship</dc:title><dc:creator>Sıcak, Yusuf</dc:creator><dc:creator>Başaran, Eyüp</dc:creator><dc:creator>Türkmenoğlu, Burçin</dc:creator><dc:creator>Öztürk, Mehmet</dc:creator><dc:subject>Antioxidant</dc:subject><dc:subject>Enzyme inhibition activity</dc:subject><dc:subject>Hydrazone</dc:subject><dc:subject>In silico</dc:subject><dc:subject>SAR</dc:subject><dc:subject>Acetylcholinesterase</dc:subject><dc:subject>Antidiabetic activity</dc:subject><dc:subject>Butyrylcholinesterase</dc:subject><dc:subject>Hydrazones</dc:subject><dc:subject>In-silico</dc:subject><dc:subject>Inhibition activity</dc:subject><dc:subject>Silico studies</dc:subject><dc:subject>Structure-activity relationships</dc:subject><dc:subject>Synthesised</dc:subject><dc:description>Herein, new N'-(substituted benzylidene)-3,5-dihydroxybenzohydrazide (1–13) series were synthesized, and their antioxidant, anticholinesterase, anti-tyrosinase, anti-urease, and antidiabetic activities were investigated together with in silico studies. The synthesized derivates were characterized using molecular spectroscopy, and the structure-activity relationships (SAR) were discussed for all tested biological assays. According to activity results, compound 3 exhibited excellent antioxidant activity in all tests, while compound 1 demonstrated the best acetylcholinesterase (AChE) inhibitory and butyrylcholinesterase (BChE) inhibitory activities. On the other hand, compound 11 showed excellent tyrosinase inhibitory (IC50:3.02±0.10 mM) and urease inhibitory (IC50:9.21±0.27 µM) activity. Moreover, among the synthesized compounds, compound 6 was detected as the best antidiabetic compound by inhibiting α-amylase (IC50:30.68±0.94 µM) and α-glycosidase (IC50:41.35±0.03 µM) enzymes, which were related with the antidiabetic activity. Molecular docking analysis confirmed AChE, BChE, tyrosinase, urease, α-amylase, and α-glucosidase inhibitory activities. In line with the findings obtained from in vitro bioactivity results and molecular docking analysis, hydrazone compounds are a suitable class of organic compounds for developing acetylcholinesterase, butyrylcholinesterase, urease, α-amylase, and α-glucosidase inhibitors. © 2024 Elsevier B.V.</dc:description><dc:publisher>Elsevier B.V.</dc:publisher><dc:date>2025</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/11135</dc:identifier><dc:identifier>https://doi.org/10.1016/j.molstruc.2024.140417</dc:identifier><dc:identifier>0022-2860</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Molecular Structure</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11135</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>